Background Each year millions of patients experience venous thromboembolic events. Due to significant morbidity and mortality associated with venous thromboembolism (VTE), prevention is critical. Deep Vein Thrombosis (DVT) is an unfortunate and potentially life-threatening condition as it can lead to fatal pulmonary thromboembolism (PTE). The objective we tried to determine the frequency of VTE in acutely ill medical patients admitted to a tertiary care hospital. The role of VTE prophylaxis, in the outcome of the acutely ill medical patient, admitted to the same hospital and to evaluate the safety profile of LMWH (Enoxaparin) administered for a period of 07-14 days or more if clinically indicated. Design and Participants. This study was conducted at the tertiary care hospital during the period 1 Jun 2017 to 30 Jun 2018. The study included 314 consecutive patients. These patients were admitted for acute medical illness were given thromboprophylaxis for 7-14 days or more. Key results Out of 314 patients who underwent thromboprophylaxis in our study, the frequency of VTE in patients of acute medical illness was 1.27 % in the prospective arm (thromboprophylaxis group) and sub-group analysis revealed higher frequency VTE in patients suffering from Acute Infection (Sepsis) as compared to various other co-morbid medical conditions. The frequency of VTE in patients of acute medical illness in the retrospective group of patients in whom thromboprophylaxis was not given was 3.5 % (p-value= 0.018). Conclusion Thromboprophylaxis with LMWH (Enoxaparin) for acutely ill medical illnesses was safe and effective. Thromboprophylaxis with LMWH (Enoxaparin) had significantly reduced the frequency of VTE in patients suffering from acute medical illness.